Treating previously untreatable cancers: How CAR‑T cell therapy could be made accessible to more patients
This image was generated by AI and may not depict real events.
CAR-T cell therapy, a treatment for previously untreatable cancers, is being made more accessible to patients in Canada through non-commercial academic research. Canadian researchers are developing affordable CAR-T therapies with comparable clinical outcomes to commercial treatments, aiming to reduce costs and improve patient access.
CAR-T cell therapy is a treatment for previously untreatable cancers. It modifies a patient's T cells to recognize and attack cancer cells. In Canada, commercial CAR-T therapies are costly and have limited accessibility. To address this, Canadian academic researchers are developing non-commercial CAR-T therapies. These therapies use the patient's own cells, which are harvested, modified, and re-injected into the body. The process involves several steps, including apheresis, cell modification, and reinfusion. Non-commercial academic production aims to reduce costs and improve patient access to these life-saving treatments.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.